Observational Recruiting
NCT04961060 on ClinicalTrials.gov
Drivers of Eosinophilic COPD Exacerbations
- Sponsor: University Medical Center Groningen
- Collaborators: Maastricht University, GlaxoSmithKline
- Enrollment: 100 (Estimated)
- Study start: 2021-07-01 (Estimated)
- Primary completion: 2024-09-01 (Estimated)
- Study completion: 2025-01-01 (Estimated)
- Allocation: N/a
- InterventionModel: N/a
- Masking: None
- PrimaryPurpose: Other
Brief Summary
Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes.
Conditions
- COPD Exacerbation
- Eosinophilia
Primary Outcome Measures
-
Change in gene expression profiles in sputum by RNA sequencing
(At admission and after 6-8 weeks after discharge.)
Change in gene expression profiles in sputum between the four groups using RNA sequencing. The differences between the expression levels of transcripts (counts) will be analyzed. -
Change in gene expression profiles in nasal epithelium by using RNA sequencing
(At admission and after 6-8 weeks after discharge.)
Change in gene expression profilesin nasal epithelium between the four groups using RNA sequencing. The differences between the expression levels of transcripts (counts) will be analyzed.
Countries
Netherlands
Locations and Investigators
-
University Maastricht, Maastricht, Netherlands (Not yet recruiting)
- Sami O Simons, PhD
-
Univesity Medical Center Groningen, Groningen, Netherlands (Recruiting)
- Lisa H van Smoorenburg, MSc.
- Maarten van den Berge, PhD
Study Officials
- Maarten van den Berge, PhD (Principal Investigator) — UMCG